BUDGET IMPACT ANALYSIS OF PALIPERIDONE PALMITATE 3-MONTHLY FOR THE TREATMENT OF SCHIZOPHRENIA IN ITALY
Author(s)
Povero M, Pradelli L
AdRes HEOR, Torino, Italy
Presentation Documents
OBJECTIVES: To estimate the impact of paliperidone palmitate 3-monthly (PP3M) with respect to paliperidone palmitate 1-monthly (PP1M) and other long-acting therapy (LAT) treatments (aripiprazole LAT, olanzapine pamoate and risperidone microspheres) for the treatment of schizophrenia in Italy. METHODS: The impact is estimated from a third party payer perspective, so only direct health costs (treatment, disease, relapse and adverse events) are considered. Patients eligible for PP3M treatment are considered: about 80% of PP3M patients come directly from PP1M, the remaining part is equally distributed between aripiprazole and risperidone. The model includes the per label required treatment-specific induction phase via PP1M. Upon relapse, according to clinical practice, patients switch to subsequent lines of therapy (oral treatment with clozapine mostly). Patients may be in stable disease, experiencing relapse, experiencing acute (prolactin-related disorders and extrapyramidal symptoms) or permanent (weight gain and diabetes) adverse events, or die. Data from Phase III PSY3011 and PSY3012 trials are used to retrieve clinical outcomes for PP1M and PP3M. Efficacy data of other LAIs and oral medicines are obtained by applying relative risks elaborated from published literature data. The economic inputs derive from official prices (for all considered drugs) and publications related to the Italian context. RESULTS: For the next 3 years, 2235, 6320, and 9316 patients, respectively, are estimated to switch to PP3M; Total savings in 3 years amounts to € 425,500 (€ 17,340 year 1, € 127,000 year 2 and € 281,160 year 3). About 40% of the savings is due to decreasing in drug costs while the rest is due to a reduction in the number of relapses. CONCLUSIONS: Based on budget impact analysis, the introduction of PP3M in Italy is completely sustainable by the National Healthcare System, as it is a cost saving option compared to the actual mix of treatment (aripiprazole, olanzapine and risperidone).
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PMH10
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Mental Health